Shots: Takeda will screen & optimize compounds derived from Debiopharm’s Debio 1454M program to identify candidates for further development to treat IBD and other GI disorders Takeda will pursue the […]readmore
Tags : GastroIntestinal Disorders
Shots: Cerevance to receive upfront technology access fee, pre/-clinical, development, commercialization milestones of up to $170M/ target and royalties on global sales of products. Takeda will support the research to […]readmore
Shots: Takeda and Frazier enter into collaboration to launch Phathom Pharmaceuticals to develop & commercialize therapies for gastrointestinal diseases and disorders Phathom to get rights to develop & exclusively commercialize […]readmore